partnering

News

Gilead taps Tentarix for cancer, inflammation projects

Gilead Sciences has put $66 million down to start a collaboration with San Diego start-up Tentarix Biotherapeutics to develop new therapeutics for cancer and inflammatory

News

Arcus and Gilead drop A2R drug for prostate cancer

Arcus and Gilead Sciences have decided not to continue the development of their A2 receptor antagonist etrumadenant in castration-resistant prostate cancer (CRPC) after an

News

Astellas adds to cell therapy drive with Poseida deal

Astellas has added another programme to its growing cell therapy pipeline via an agreement with Poseida on an off-the-shelf CAR-T therapy for solid tumours.

News

Dosing prompts Novartis to tap Ionis for second Lp(a) drug

Novartis has turned to Ionis for another cardiovascular disease drug, putting $60 million down for a follow-up to lipoprotein(a)-targeting drug pelacarsen, which is now in

News

Astellas builds in protein degraders with PeptiDream deal

Astellas has made another move into the area of protein degrader drugs, announcing its second partnership in the category in the space of two months.

News

Pieris wields axe after losing AZ as partner for elarekibep

AstraZeneca has terminated a partnership with Pieris Pharmaceuticals on respiratory drug candidate elarekibep, forcing the latter to slash staff and look into its “strateg

Gilead taps Tentarix for cancer, inflammation projects

Arcus and Gilead drop A2R drug for prostate cancer

Astellas adds to cell therapy drive with Poseida deal

Dosing prompts Novartis to tap Ionis for second Lp(a) drug

Astellas builds in protein degraders with PeptiDream deal

Pieris wields axe after losing AZ as partner for elarekibep

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

partnering

Editor's Picks